SIM
VRTX icon

Spark Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Spark Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-8,900
Closed -$1.72M – 818
2018
Q3 		$1.72M Buy
8,900
+4,100
+85% +$730K 0.1% 288
2018
Q2 		$815K Sell
4,800
-10,300
-68% -$1.6M 0.05% 390
2018
Q1 		$2.46M Sell
15,100
-37,400
-71% -$6.11M 0.16% 196
2017
Q4 		$7.87M Sell
52,500
-25,600
-33% -$3.79M 0.42% 61
2017
Q3 		$11.9M Hold
78,100
– – 0.64% 22
2017
Q2 		$10.1M Buy
78,100
+39,800
+104% +$4.79M 0.62% 21
2017
Q1 		$4.19M Buy
+38,300
New +$3.37M 0.26% 100

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Spark Investment Management's VRTX Position: Q4 2018 in Review

Spark Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2018, closing a stake of 8,900 shares — an estimated $1.72M sold.

Spark Investment Management first reported a position in VRTX in Q1 2017 and held it in 7 quarters. The position peaked at $11.9M in Q3 2017. 705 funds tracked by Wall St. Rank hold VRTX as of Q4 2018.

  • Spark Investment Management reported no remaining Vertex Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Spark Investment Management sold 8,900 Vertex Pharmaceuticals shares in Q4 2018, an estimated $1.72M.
  • Spark Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and held it in 7 quarters.
  • Spark Investment Management's Vertex Pharmaceuticals position peaked at $11.9M in Q3 2017.
  • 705 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2018.

Based on Spark Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.